Cambridge Healthtech Institute’s Ninth Annual
Part Two: Emerging Vaccine Technologies
August 12-13, 2014
An ever-expanding array of technologies and approaches are being employed to create more efficacious vaccines and advance the field, including developing predictive models and Synthetic Biology. Next- Generation Sequencing (NGS) is also being used to elucidate viral evolution in an effort to more deeply understand infection.
The Ninth annual “Novel Vaccines” meeting tackles these emerging technologies in an effort to crystallize where the field is headed, along with novel modes and routes of delivery, such as patches, VLPs and microparticles. Ways to test vaccines in order to ensure quality will also be explored, including rapid microbiological methods (RMM), potency tests, and large-scale arrays. Vaccine stability and targeting specific populations will also be discussed as part of the push to achieve more effective vaccines and support vaccine development.
Synthetic Genomics to Address Emerging Threats and Global Supply Challenges
Bolyn Hubby, Ph.D., Senior Director, Head, Vaccine and Phage R&D, Synthetic Genomics Vaccines, Inc.
Databases and in silico Tools for Vaccine Design
Yongqun (Oliver) He, D.V.M., Ph.D., Associate Professor, Microbiology and Immunology, Affiliated Member, Center for Computational Medicine and Biology, Member, Comprehensive Cancer Center, University of Michigan
Genomic Analysis of Vaccine Response In Humans
W. Nicholas Haining, BM, BCh, Assistant Professor of Pediatrics, Harvard Medical School; Scientific Co-Leader, HSCT Program, Department of Pediatric Oncology, Dana-Farber Cancer Institute Children's Hospital; Associate Member, Broad Institute of Harvard and MIT
Identification of Novel Vaccine Candidates Using a Robust Immunogen Optimization System
Sean Du, Ph.D., COO, Corporate, Altravax, Inc.
Innovative Preclinical Models for Developing Staphylococcus aureus Vaccines
Fabio Bagnoli, Ph.D., Project Leader, Novartis Vaccines and Diagnostics
Engineering Cancer Immunotherapy One (DNA) Sequence at a Time
Mark Bagarazzi, Ph.D., CMO, Inovio Pharmaceuticals
Nanosponge Toxoid for Safe and Effective Vaccination
Liangfang Zhang, Ph.D., Associate Professor, Nanoengineering and Moores Cancer Center, University of California, San Diego
Development of a Dendritic Cell Receptor-Targeted Multi-Antigen HIV Vaccine that Generates Both Cellular and Humoral Immune Responses Without Adjuvant
Rajan George, Ph.D., President & CSO, Akshaya Bio, Inc.
An Ultra-Low Dose Live-Attenuated Influenza Vaccine – An Opportunity to Overcome Current Manufacturing Bottlenecks
J. Robert Coleman, Ph.D., MBA, Co-Founder, Executive Vice President, Vaccine Development, Codagneix, Inc.
Robust Induction of Cytotoxic T Lymphocyte (CTL) Response through Low-Frequency Sonophoresis Assisted Transcutaneous Immunization
Diviya Sinha, Ph.D., Technical Instructor, Biology, Massachusetts Institute of Technology
Tuning the Direction and Magnitude of the Immune Response with New Nanomaterial-Based Vaccines
Tarek Fahmy, Ph.D., Associate Professor, Biomedical Engineering, Engineering & Applied Science, Yale University